Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 5/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.65 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.65 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.65 |
| ▸ | DPP4 | P27487 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.65 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.65 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.65 |
| ▸ | GAPDH | P04406 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | STAT6 | P42226 | 1/20 | 0.65 |
| ▸ | PI4KA | P42356 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.65 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.65 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.65 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.65 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL932846 | 0.94 | ADORA1 (0.65) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL13269154 | 0.92 | PDE2A (0.66) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL13269131 | 0.92 | ADORA1 (0.62) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL13269088 | 0.92 | ADORA1 (0.62) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL4541368 | 0.92 | ADORA1 (0.64) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL622588 | 0.92 | ADORA1 (0.69) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL13268725 | 0.91 | ADORA1 (0.60) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL22458248 | 0.91 | ADORA1 (0.65) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL14696730 | 0.91 | ADORA1 (0.60) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL4537888 | 0.91 | TRDMT1 (0.64) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753432-B2 | Compound with analgesic effect for use in prevention and treatment of pain | ACADEMIA SINICA (TW) | 2023-09-12 | — | — | US | claimed |
| EP-3573996-B1 | COMPOUND WITH ANALGESIC EFFECT FOR USE IN PREVENTION AND TREATMENT OF PAIN | ACADEMIA SINICA (TW) | 2022-06-15 | — | — | EP | claimed |
| US-20210205399-A1 | Pharmaceutical Composition for Promoting Neurogenesis and Method of Utilizing Gastrodia Elata Extract or Adenosine Analog for Promoting Neurogenesis | AXR PHARMA INC. (TW) | 2021-07-08 | — | — | US | claimed |
| US-20200054708-A1 | PHARMACEUTICAL COMPOSITION FOR PROMOTING NEUROGENESIS AND METHOD OF UTILIZING GASTRODIA ELATA EXTRACT OR ADENOSINE ANALOG FOR PROMOTING NEUROGENESIS | AMX Pharma Inc. (TW) | 2020-02-20 | — | — | US | claimed |
| WO-2018140734-A1 | COMPOUND WITH ANALGESIC EFFECT FOR USE IN PREVENTION AND TREATMENT OF PAIN | ACADEMIA SINICA (TW) | 2018-08-02 | — | — | WO | claimed |
| US-20170224716-A1 | Methods and Compositions for Treating Pain | ACADEMIA SINICA (TW) | 2017-08-10 | — | — | US | claimed |
| EP-2849566-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | Academia Sinica (TW) | 2015-03-25 | — | — | EP | claimed |
| CN-104363757-A | Methods and compositions for treating pain | ACADEMIA SINICA | 2015-02-18 | — | — | CN | claimed |
| US-20150038445-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ACADEMIA SINICA (TW) | 2015-02-05 | — | — | US | claimed |
| CN-101602786-B | N<6>-substituted adenosine derivative, preparation method thereof, drug composition and application | INST MATERIA MEDICA CAMS | 2014-04-30 | — | — | CN | claimed |
| WO-2013120078-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ACADEMIA SINICA (TW) | 2013-08-15 | — | — | WO | claimed |
| US-20130045942-A1 | N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2013-02-21 | — | — | US | claimed |
| EP-2511283-A1 | N6-SUBSTITUTED ADENOSINE DERIVATIVES, N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2012-10-17 | — | — | EP | claimed |
| US-8129357-B2 | N6-(4-hydroxybenzyl)adenosine; Gastrodia extract; neurodegenerative Huntington's disease; trinucleotide repeat disease; hypoglycemic; neurological antiinflammatory; amination of 6-chloropurine ribonucleoside with 4-hydroxybenzylamine; condensation of adenosine with 4-methoxybenzoyl chloride | ACADEMIA SINICA (TW) | 2012-03-06 | — | — | US | claimed |
| CN-101602786-A | N 6-substituted adenosines derivative, its method for making and pharmaceutical composition and purposes | INST MATERIA MEDICA CAMS (CN) | 2009-12-16 | — | — | CN | claimed |
| US-20080176816-A1 | Method of making and using an adenosine analogue | ACADEMIA SINICA | 2008-07-24 | — | — | US | claimed |
| CN-118063290-A | Hexadibenzyl compounds and application thereof in treatment and prevention of diabetes | 中国医学科学院药物研究所 | 2024-05-24 | — | — | CN | disclosed |
| CN-118063291-A | Application of tetrabenzyl compounds in treatment and prevention of diabetes | 中国医学科学院药物研究所 | 2024-05-24 | — | — | CN | disclosed |
| WO-2009071691-A2 | OXINDOLE DERIVATIVES AND THE USE THEREOF AS A MEDICATION | ABBOTT GMBH & CO. KG (DE) | 2009-06-11 | — | — | WO | disclosed |
| US-20080176816-A1 | Method of making and using an adenosine analogue | ACADEMIA SINICA | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176816-A1 | Method of making and using an adenosine analogue | HTT, ADA, GDA | ADORA1 13/4885SMN1; SMN2 321/4885ADORA3 11/4885 |
| US-20170224716-A1 | Methods and Compositions for Treating Pain | ADORA2A, P2RX3, ADORA1 | ADORA1 3/4885SMN1; SMN2 2487/4885ADORA3 12/4885 |
| US-20150038445-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | OPRK1, ADORA2A, P2RX3 | ADORA1 6/4885SMN1; SMN2 2370/4885ADORA3 8/4885 |
| US-11753432-B2 | Compound with analgesic effect for use in prevention and treatment of pain | ADORA2B, ADORA1, ADORA3 | ADORA1 2/4885SMN1; SMN2 1353/4885ADORA3 3/4885 |
| US-20130045942-A1 | N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF | ADORA2A, ADORA3, ADORA1 | ADORA1 3/4885SMN1; SMN2 330/4885ADORA3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.